, CEL-SCI CORPORATION
(Amex: CVM) announces that its CEL-1000 immune -modulating peptide was shown in
mice to protect against viral encephalitis, a potentially lethal inflammation
of the brain. government's list of priority
pathogens for bio-defense research. These data were presented yesterday by
Dr. government has included in the
second highest level immediate risk category for use as biological weapons --
The Venezuelan Equine Encephalitis (VEE ), the Eastern Equine Encephalitis
(EEE) and Western Equine Encephalitis (WEE).
Daniel Zimmerman , Senior Vice President of Research, Cellular Immunology
of CEL-SCI commented, "We believe that there could be significant potential
for CEL-1000 as a possible treatment for viral encephalitis."
CEL-1000 is a modified version of a human immune-based protein known to
bind to both human and mouse immune cells and appears to act by enhancing the
host's protective immune response. The Company has operations in Vienna,
Virginia and Baltimore, Maryland.

lyme viral

aRigen has filed several patents to cover
the production method and use of the topical formulation for the
treatment of herpes zoster. In
the United States, the most frequently reported causes are herpes simplex
virus type 1 (HSV -1) and viruses spread by insects. Antiviral drugs are available
for the treatment of herpes simplex virus infections, but antiviral drugs are
not available for other encephalitis causing viruses. Earlier studies
in Dr.

lyme herpes

5 to 3. These include: The West
Nile Virus and three viruses that the U. Rosenthal's lab with Dr.

spirochetal support

Janus Pharmaceuticals Inc. Announces IND Filing for JA-001

Janus plans to conduct clinical studies evaluating the safety and
efficacy of JA-001 (also known as ARYS-01 cream ) a topical formulation
of sorivudine for the treatment of herpes zoster infections. The annualized incidence
of herpes zoster is about 1.
Janus currently has three products in development: JA-001; JA-002, a
gel formulation of a novel proprietary antibiotic targeting prevention
and treatment of bacterial infections of the skin; and JA-003, an
antibiotic cream for the treatment of acne.com

groups diseases

Business Editors/Healthcare Editors

LOS ANGELES----

Cream Formulation of Anti-Zoster Drug to Be Evaluated in
Phase 1 Studies in the United States

Janus Pharmaceuticals Inc. Sorivudine was originally discovered
by Yamasa Corporation of Chiba , Japan, and is being developed as a
topical formulation by Janus under a joint development agreement with
aRigen Inc.0 cases per 1000 persons, or more
than 500,000 cases on average per year in the United States. Janus is also actively
pursuing the acquisition of additional products which will complement
their growing product portfolio.
These studies suggest that CEL-1000 modulates the immune system to more
effectively fight different diseases.

conditions spirochetal

of Tokyo, Japan.S.
Neena Goel at Northeastern Ohio Universities College of Medicine, Rootstown,
Ohio at the American Association of Immunologists Annual Meeting in San Diego.S.

health disease

Over 90
percent of adults in the United States have serologic evidence of VZV
infection and are at risk for herpes zoster. Kenneth S.
The work was conducted with the support of two grants from the National
Institute of Allergy and Infectious Diseases (NIAID).

When used in this report, the words "intends," "believes," "anticipated"
and "expects" and similar expressions are intended to identify forward-looking
statements. Factors
that could cause or contribute to such differences include, an inability to
duplicate the clinical results demonstrated in clinical studies, timely
development of any potential products that can be shown to be safe and
effective, receiving necessary regulatory approvals, difficulties in
manufacturing any of the Company's potential products, inability to raise the
necessary capital and the risk factors set forth from time to time in CEL-SCI
Corporation's SEC filings, including but not limited to its report on Form 10-
K/A for the year ended September 30, 2004.

support infectious

(Janus) announced the filing of an
Investigational New Drug application for a topical formulation of an
anti-viral product with previously demonstrated activity against the
varicella zoster virus (VZV) in both preclinical and clinical studies. For more information about Janus and
its products please visit www.januspharma. The Company undertakes no
obligation to publicly release the result of any revision to these forward-
looking statements which may be made to reflect the events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events.

disease groups

CEL-1000 Peptide Effective Against Viral Encephalitis in Mice

Rosenthal, Professor of Microbiology and Immunology, and Dr.

groups diseases

More than 100 different types of viruses can cause acute encephalitis. Other researchers have shown
that CEL-1000 also protects against malaria and cancer in animal models. Such statements are subject to risks and uncertainties which
could cause actual results to differ materially from those projected.

support viral

Sorivudine is an antiviral nucleoside analog which is transported
into viral-infected cells and converted to monophosphate analogs by
virus-encoded thymidine kinases. Viral encephalitis is on the U.

diseases disease

Herpes zoster, also known as shingles, results from a reactivation
of a primary varicella-zoster virus infection (chicken pox ).
Janus Pharmaceuticals (Janus) is a specialty pharmaceutical
company founded in 2004 that has a growing portfolio of topical
pharmaceutical products for the treatment of infectious diseases.

VIENNA, Va. Neena Goel had shown high levels of protection
in animal studies against Herpes Simplex Virus.
CEL-SCI Corporation is developing new immune system based treatments for
cancer and infectious diseases.

diseases groups

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)